Nq
Universal Platforms for
Vaccine Development

Platform Advantages

Bringing Technology from Georgia Tech and the Scripps Research Institute to Industry
Go to Accelerate Development

Accelerate Development

Our system can take your drug discovery timeline from years to months.

Click to learn more.

Go to REDUCE COSTS

REDUCE COSTS

We can save most companies around 40% on testing their vaccine candidates. Our tests can confirm negative immunigenocity with a fraction of the trials used in current testing.

Go to Flexibility

Flexibility

Services can be performed at our labs or in yours, or with approved CROs.

Tested Technology

NanoCliq’s technology has been vested by scientists at two of the world’s leading research institutions.

World's First leishmanias vaccine

Built on
the nQ Platform

NanoCliq's vaccine for Leishmaniasis is built on the patent-pending nQ nanoparticle platform conjugated with a specialized carbohydrate signature for Leishmaniasis. Studies conducted with our collaborating lab in Brazil have demonstrated protection from the disease in inoculated laboratory animals. The company is currently raising funds to complete FDA work and begin human trials.

  • of contracting Leishmania each year

  • of Leishmaniasis Annually

  • The Leishmania vaccine was prototyped and built in less than a year.

  • Unlike common expensive chicken-egg vaccines, nQ vaccines are produced by engineered bacteria.

OUR TEAM

Our international team of superstars, from MIT, Georgia Tech, Emory, Scripps, and Rice Universities

INDRA DATTA

CEO
Indra Datta holds Masters degrees in Computer Science from Rice University where he also worked in neuroscience research. He formerly founded and ran the medical data storage company MDVault.net.

Dr. MG Finn

Science Advisor

Richard DiMonda

Business Advisor

Next Diseases

Latest news